Free tool
FAERS Monitor: Voyxact
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761434 or its brand name (Voyxact, Sibeprenlimab-Szsi). Reports on generic versions are filed under their own applications.
Reports
689
Serious
114
17% of reports
Hospitalization
56
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- injection site pain100
- injection site swelling75
- fatigue68
- injection site erythema51
- injection site pruritus47
- nasopharyngitis43
- cough32
- injection site bruising32
- nausea32
- dizziness29
- headache24
- diarrhoea23
- illness23
- underdose23
- upper respiratory tract infection22
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 2 |
| 2025 | 6 |
| 2026 | 681 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,470 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| injection site swellingSignal | 75 | 29.9 | 24.2 | 2,072 |
| injection site pruritusSignal | 47 | 21.4 | 16.3 | 897 |
| upper respiratory tract infectionSignal | 22 | 14.5 | 9.6 | 265 |
| injection site erythemaSignal | 51 | 12.6 | 9.6 | 534 |
| injection site bruisingSignal | 32 | 12.2 | 8.7 | 321 |
| injection site painSignal | 100 | 10.0 | 8.3 | 808 |
| underdoseSignal | 23 | 9.6 | 6.4 | 170 |
| nasopharyngitisSignal | 43 | 7.1 | 5.3 | 222 |
| illnessSignal | 23 | 6.8 | 4.6 | 109 |
| coughSignal | 32 | 3.5 | 2.5 | 55 |
| fatigueSignal | 68 | 2.7 | 2.1 | 72 |
| dizziness | 29 | 1.8 | 1.2 | 9 |
| nausea | 32 | 1.2 | 0.9 | 1 |
| headache | 24 | 1.2 | 0.8 | 0 |
| diarrhoea | 23 | 1.1 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.